These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


157 related items for PubMed ID: 10637920

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Are the ATS (American Thoracic Society) and the ERS (European Respiratory Society) correct in not recommending routine tumor marker assays foeening, staging, or evaluation of non-small cell lung cancer?].
    Watine J, Charet JC.
    Rev Mal Respir; 1999 Apr; 16(2):139-49. PubMed ID: 10339757
    [Abstract] [Full Text] [Related]

  • 3. [Value of tumor markers for screening and diagnosis (except prognostic and surveillance values) in primary bronchial cancers].
    Grivaux M.
    Rev Mal Respir; 1997 Apr; 14 Suppl 3():S15-9. PubMed ID: 9229742
    [No Abstract] [Full Text] [Related]

  • 4. [Which tumor markers should be used in primary bronchial cancers?].
    Schuller MP, Carrat F, Urban T, Lebeau B.
    Rev Mal Respir; 1997 Apr; 14 Suppl 3():S9-14. PubMed ID: 9229750
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Value of tumor markers in surveillance of primary bronchial cancers and to evaluate therapy].
    Sculier JP.
    Rev Mal Respir; 1997 Apr; 14 Suppl 3():S23-6. PubMed ID: 9229744
    [No Abstract] [Full Text] [Related]

  • 7. Prognostic markers for stage I non-small cell lung cancer.
    Mizuguchi S, Nishiyama N.
    Lung Cancer; 2008 Feb; 59(2):274-5. PubMed ID: 18055061
    [No Abstract] [Full Text] [Related]

  • 8. [Usefulness of CYFRA21-1 as a tumor marker of non-small-cell lung cancer].
    Tan Y, Zhang P, Zheng C.
    Zhonghua Zhong Liu Za Zhi; 1999 Jul; 21(4):287-9. PubMed ID: 11776818
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J, Philipp M, Velcovsky HG, Morr H, Katz N.
    Anticancer Res; 2003 Jul; 23(2A):885-93. PubMed ID: 12820318
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F, Aydiner A, Topuz E, Yasasever V, Karadeniz A, Saip P.
    J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
    Kasimir-Bauer S, Schleucher N, Weber R, Neumann R, Seeber S.
    Oncol Rep; 2003 Dec; 10(2):475-82. PubMed ID: 12579292
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Consensus conference. January 9 1992. Nice. Pretherapeutic evaluation of the extension of non small-cell bronchial carcinoma. French Language Society of Pneumology].
    Rev Pneumol Clin; 1992 Dec; 48(1):35-40. PubMed ID: 1318572
    [No Abstract] [Full Text] [Related]

  • 18. [Value of serial tumor markers for determining the prognosis and predicting treatment response and survival].
    Souquet PJ.
    Rev Mal Respir; 1997 Apr; 14 Suppl 3():S20-2. PubMed ID: 9229743
    [No Abstract] [Full Text] [Related]

  • 19. [CYFRA 21-1].
    Pujol JL.
    Rev Mal Respir; 1997 Apr; 14 Suppl 3():S31-6. PubMed ID: 9229747
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 8.